Analytical Data
-
Gene name
HLA-A*02:01&B2M&HPV16 E6(KLPQLCTEL) Monomer
- Application
-
Alternative Names
rHuHLA-A*0201 HPV16 E6 complex Protein
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&KLPQLCTEL
-
Molecular Weight
53-63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/HPV16 E6 (KLPQLCTEL) monomeric recombinant protein is critical in the field of immunology and cancer research, particularly in understanding human papillomavirus (HPV) and its role in cervical cancer. HLA-A*02:01 is one of the most prevalent human leukocyte antigens involved in presenting viral peptides to T cells, facilitating immune responses. The HPV16 E6 protein, specifically the peptide KLPQLCTEL, is a key target because it is frequently expressed in HPV-positive cancers and has been implicated in immune evasion strategies of the virus. By creating a recombinant monomeric protein that combines HLA-A*02:01, beta-2-microglobulin (B2M), and the HPV16 E6 peptide, researchers aim to better understand the molecular mechanisms of T cell recognition and response. This research holds potential for developing innovative therapeutic strategies, including vaccines and immune checkpoint inhibitors, designed to enhance anti-tumor immune responses in patients with HPV-related malignancies. The synthesis and characterization of this recombinant protein not only provide insights into peptide-HLA interactions but also pave the way for personalized medicine approaches in combating HPV-associated diseases.
